Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App helps cancer patients track symptoms and improve care

NCT ID NCT05112198

Symptom relief Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a digital tool called Noona that lets advanced cancer patients track their symptoms from home. 190 adults with advanced lung or gastrointestinal cancer used the app to log symptoms and received prompts to report them weekly. The goal was to see if this improves quality of life and helps doctors manage symptoms better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Noona web-based symptom tracking tool
What this could lead to
If successful, this could show that digital symptom tracking helps improve quality of life and symptom management for advanced cancer patients.
What could go wrong
This is a completed study with 190 participants, so results are available but may not apply to all cancer types or settings. The tool relies on patient engagement, which may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

190 people

The number who actually took part.

Started

Mar 2018

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individuals (men and women) aged 18 years or older 2. Biopsy proven (recurrent or metastatic) advanced lung or gastrointestinal cancer 3. No limit on prior lines of therapy in the metastatic setting 4. ECOG performance status of 0-2 5. Estimated life expectancy of at least 6 months 6. Access to smartphone, tablet or computer with capability to utilize symptom tracking application 7. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures 8. Willing and able to comply with all study procedures Exclusion Criteria: 1. Concurrent disease or condition that interferes with participation or safety 2. Non-english speaking, as the application is developed in the english language 3. Non-castrate resistant prostate cancer 4. Enrolled in other non-therapeutic or therapeutic clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced gastrointestinal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system cancer lung cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Quality of life

Contacts and locations

Locations

  • Stanford Cancer Institute

    Palo Alto, California, 94305, United States

  • UCSF Helen Diller Medical Center

    San Francisco, California, 94115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.